Previous studies demonstrate that PARP-1 is downregulated in SSc by increased DNA methylation in the PARP-1 promoter region (44), and XRCC1 polymorphisms are associated with increased endogenous DNA damage and the presence of antinuclear and anticentromere antibodies in SSc patients (6). Here, PARP1 is linked to systemic sclerosis.